Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of acetylsalicylic acid (ASA), a nonsteroidal anti-inflammatory drug (NSAID). Enteric coating is designed to bypass initial gastric dissolution to reduce local mucosal irritation, though it does not eliminate the systemic risk of gastric ulceration.
## Primary Indications
* **Cardiovascular:** Prophylaxis of myocardial infarction (MI), ischemic stroke, and transient ischemic attacks.
* **Vascular:** Secondary prevention in patients with coronary or peripheral artery disease.
* **Inflammatory (High Dose):** Rheumatoid arthritis, juvenile idiopathic arthritis (JIA).
* **Acute Coronary Syndrome (ACS):** Initial management (generally non-enteric, chewable aspirin preferred for rapid absorption).
## Adult Dosing
* **Cardiovascular Prophylaxis:** 75–162 mg orally once daily.
* **Acute Coronary Syndrome (Initial):** 162–325 mg (non-enteric preferred).
* **Inflammatory Conditions:** 2.4–3.6 g/day divided into 3–4 doses; titrate to response or salicylate serum levels.
## Pediatric Dosing
* **JIA / Inflammatory Conditions:** 60–100 mg/kg/day divided into 4–6 doses; monitor serum salicylate levels (target 15–30 mg/dL).
* **Kawasaki Disease:** Initial 80–100 mg/kg/day in 4 divided doses until afebrile or day 14 of illness, followed by 3–5 mg/kg once daily for antiplatelet effect.
* **WARNING:** Reye’s syndrome risk. Aspirin use is strictly contraindicated in children/adolescents with suspected or confirmed viral infections (e.g., flu, varicella).
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Avoid in severe renal failure (CrCl < 10 mL/min).
* **Hepatic Impairment:** Avoid in severe hepatic failure; increased risk of bleeding and hepatotoxicity.
## Contraindications
* Hypersensitivity to salicylates or NSAIDs.
* Active peptic ulcer disease or pathological bleeding.
* Hemophilia or other bleeding disorders.
* Children/teenagers with viral infections (Reye's syndrome risk).
* Asthma associated with "aspirin-exacerbated respiratory disease" (AERD).
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, gastric ulceration, occult blood loss.
* **Hematologic:** Prolonged bleeding time, increased risk of intracranial hemorrhage.
* **Otic (High Dose):** Tinnitus, hearing loss (often reversible).
* **Renal:** Acute kidney injury, interstitial nephritis.
## Key Drug Interactions
* **Anticoagulants/Antiplatelets:** (e.g., Warfarin, Clopidogrel, DOACs) Significant increase in major bleeding risk.
* **NSAIDs:** (e.g., Ibuprofen) May interfere with the cardioprotective effect of low-dose aspirin; space ibuprofen 8 hours after or 30 minutes before aspirin.
* **Corticosteroids:** Increased risk of GI ulceration.
* **Alcohol:** Increased risk of GI mucosal injury.
## Monitoring
* **Chronic Use:** Hemoglobin/Hematocrit (occult bleeding), stool guaiac testing if clinically suspicious, baseline and periodic serum creatinine.
* **High-Dose Therapy:** Serum salicylate levels (therapeutic range 15–30 mg/dL).
* **Toxicity:** Signs of overdose include hyperpnea, tachypnea, tinnitus, metabolic acidosis, or altered mental status.
## Clinical Pearls
* **Absorption:** Enteric coating significant delays onset of action; never use enteric-coated aspirin in an acute MI setting if a chewable/plain formulation is available.
* **Compliance:** Long-term low-dose therapy is highly effective for secondary cardiovascular prevention, but adherence is critical.
* **AERD:** Patients with asthma, rhinosinusitis, and nasal polyps may experience severe bronchospasm upon aspirin exposure.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages, contraindications, and drug interactions against current local institutional protocols and the latest prescribing information (e.g., FDA/EMA labels or Lexicomp/UpToDate).*
